Entries |
Document | Title | Date |
20080255344 | Immuno-Adsorbers For Treatment of Inflammations - The invention relates to an immunological adsorber for treating inflammations, in particular for eliminating complement factors, and, optionally, additional sepsis-mediators, such as, TNF and interleukins from body fluids. The invention also relates to a method for the production and use of said immunological adsorber. The aim of the invention is to develop a modular immunoadsorption system, in particular for extracorporal detoxification, which enables plasma and tissue levels, which are specific to the patient, to be reduced. The inventive immunological adsorber consists of organic or synthetic polymer support materials whereon polyclonal and monoclonal antibodies are connected which are oriented counter to the complement factor C3a and/or C5a. In a preferred embodiment, other antibodies which are oriented counter to the additional inflammation mediators, are connected to the support. In a particularly advantageous embodiment, the invention relates to an immunoadsorber provided with antibodies against C5a and IL6. | 10-16-2008 |
20080319173 | Blood group antigen fusion polypeptides and methods of use thereof - The present invention provides compositions and methods for treating or preventing antibody mediated graft rejection. | 12-25-2008 |
20090093618 | STREPTAVIDIN-BIOTIN-LINK ANTIBODY-HAPTEN SYSTEM - The present invention provides antibodies comprising an antigen recognition domain that specifically binds to a metal chelate: mutant antibodies comprising a reactive site not present in the wild-type of the antibody, wherein the reactive site is in a position proximate to or within the antigen recognition domain; and methods of using such antibodies to diagnose and treat disease. | 04-09-2009 |
20090099342 | Process for Preparing Composite Particles, Composite Particles Obtained, and Their Use in a Diagnostic Test - The invention relates to a process for preparing composite particles by encapsulation of an organic-phase-depleted emulsion by polymerization, said emulsion consisting of droplets of inorganic emulsion comprising an organic phase and inorganic nanoparticles distributed in said organic phase, characterized in that the polymerization is carried out using, as the polymerization monomer, from 60% to 100% of at least one crosslinking agent and from 0% to 40% of at least one hydrophobic monomer, it being understood that at least 95% of the crosslinking agent(s) are hydrophobic. The invention further relates to the particles thus obtained, and their use in diagnostics. | 04-16-2009 |
20090264628 | CRYSTAL STRUCTURE OF HUMAN UROKINASE PLASMINOGEN ACTIVATOR AMINO TEMINAL FRAGMENT BOUND TO ITS RECEPTOR - Urokinase-type plasminogen activator (uPA) binds its cellular receptor (uPAR) with high affinity, thus localizing the generation of plasmin from plasminogen on the surface of a variety of cells. Disclosed herein is the structure of suPAR (uPAR | 10-22-2009 |
20090275738 | Use of A33 antigens and jam-it - The present invention relates to compositions and methods of treating and diagnosing disorders characterized the by the presence of antigens associated with inflammatory diseases and/or cancer. | 11-05-2009 |
20090286963 | ANTIGENIC FUSION PROTEIN CARRYING GAL ALPHA1,3GAL EPITOPES - The present invention relates to an antigenic fusionprotein, which carries multiple Galα1,3Gal epitopes. The fusion protein according to the invention may also be comprised of a heavily glycosylated mucin part, which mediates binding to selectins, such as PSGL-1, and a part, which exhibits immunoglobulin properties, such as the Fc part of IgG. The fusionprotein according to the invention is preferably used as an absorber to prevent a hyperacute rejection of a xenotransplant, such as a pig tissue or organ transplanted into a human patient. In addition, the invention relates to a method for the prevention of a hyperacute rejection reaction in a patient who is to receive a xenotransplant. | 11-19-2009 |
20090306349 | BINDING PARTNERS WITH IMMUNOGLOBULIN DOMAINS MODIFIED TO HAVE EXTENDED HALF-LIFE - A method for conjugation of glycosylated Fc-containing proteins is described. The method comprises carbamate chemistry performed and neutral pH or below and the resulting Fc-containing protein are expected to retain tertiary structure and therefore Fc-related bioactivity such as FcR binding, the ability to bind Clq, in addition to retaining ligand binding capabilities related to the incorporation of a ligand binding peptide or other polypeptide which has binding specificity. The method is exemplified using an erythropoietin-mimetic peptide fused to a human IgG1 antibody constant domain comprising a hinge, CH2 and CH3. | 12-10-2009 |
20100036102 | NOVEL CHELATING AGENTS AND HIGHLY LUMINESCENT AND STABLE CHELATES AND THEIR USE - This invention relates to a group of novel chelating agents, novel chelates, biomolecules labeled with said chelates or chelating agents as well as solid supports conjugated with said chelates, chelating agents or labeled biomolecules. Especially the invention relates to novel chelating agents useful in solid phase synthesis of oligonucleotides or oligopeptides and the oligonucleotides and oligopeptides so obtained. | 02-11-2010 |
20100069616 | ENGINEERED ANTIBODY-NANOPARTICLE CONJUGATES - Conjugates of a C-terminal modified diabody and a nanoparticle are provided in which the C-terminal modification introduces a cysteine residue at a C-terminus of the diabody and the diabody is covalently linked to the nanoparticle via a heterobiofunctional linker attached to the introduced cysteine residue. | 03-18-2010 |
20100087632 | VEGF-Binding Fusion Proteins and Therapeutic Uses Thereof - Fusion proteins which bind and inhibit vascular endothelial growth factor (VEGF). The VEGF-binding fusion proteins are therapeutically useful for treating VEGF-associated conditions and diseases, and are specifically designed for local administration to specific organs, tissues, and/or cells. | 04-08-2010 |
20100093981 | CARBAMOYLATION OF AMINES, THIOPHENOLS, MERCAPTANES AND PHENOLS EMPLOYING ORGANIC AZIDES - The present invention relates to carbamoylation of amines, mercaptanes, thiophenols and phenols employing organic azides. More specifically, the invention relates to a method for generating urea derivatives, thiocarbamate derivatives and carbamate derivatives, and is based on the intermediate formation of isocyanate, starting from an organic azide. The reaction as described is useful in applications for modified nucleoside synthesis, oligonucleotide synthesis, as well as modification, labeling and conjugation of polymers and biomolecules. | 04-15-2010 |
20100105876 | Method for the oligomerisation of peptides - The present invention concerns an oligomer comprising more than 2 units, wherein each unit comprises a peptidic domain capable of oligomerizing and a domain capable of binding to an acceptor (ligand), wherein the oligomerizing domain is not an antibody or a functional antibody fragment from the constant region. Also described is the use and synthesis of this oligomer. | 04-29-2010 |
20100113751 | PURIFICATION OF ACIDIC PROTEINS USING CERAMIC HYDROXYAPATITE CHROMATOGRAPHY - The present invention provides a method of removing product-related inactive or partially active species, high molecular weight aggregates, as well as other process-related impurities from preparations of acidic proteins by using ceramic hydroxyapatite chromatography. | 05-06-2010 |
20100113752 | Immunodisplacement Electrophoresis - The disclosure teaches a method for the analysis of a sample by electrophoresis, making use of a binding partner for a target compound or group of target compounds which may be present in the sample. The disclosure further teaches a kit for use in an electrophoretic analysis, to a modified antibody or fragment thereof, and to specific uses of the kit or modified antibody or fragment thereof. | 05-06-2010 |
20100113753 | Methods for preparing T-cells for cell therapy - T-cells are generated with enhanced immunostimulatory capabilities for use in self therapy treatment protocols, by utilizing a biodegradable device with a biodegradable support that has one or more agents that are reactive to T-cell surface moieties. The biodegradable devices are mixed with the T-cells sufficiently so that the one or more agents cross-link with the T-cells' surface moieties and deliver a signal to the T-cells to enhance immunostimulatory capabilities. | 05-06-2010 |
20100190966 | METHOD FOR IMMOBILIZING GLYCOPROTEIN - A method for immobilizing glycoprotein is disclosed. A surface is provided. Next, a boronic acid is contacted to the surface. The boronic acid is represented as Y—R—B—(OH) | 07-29-2010 |
20100234579 | SILVER NANOPARTICLE BINDING AGENT CONJUGATES BASED ON MOIETIES WITH TRIPLE CYCLIC DISULFIDE ANCHORING GROUPS - The present invention concerns the use of binding agent-functionalized silver nanoparticles for a variety of uses, including molecular diagnostic labels, synthons in programmable materials synthesis approaches, and functional components for nanoelectronic devices. More specifically, the invention provides a new strategy for preparing silver nanoparticle-binding agent conjugates that are based upon moieties with triple cyclic disulfide-anchoring groups. | 09-16-2010 |
20100249385 | WATER-SOLUBLE FLUORO-SUBSTITUTED CYANINE DYES AS REACTIVE FLUORESCENCE LABELLING REAGENTS - Disclosed are cyanine dyes that are useful for labelling and detecting biological and other materials. The dyes are of formula (I): | 09-30-2010 |
20100273991 | METHOD OF COVALENTLY MODIFYING PROTEINS WITH ORGANIC MOLECULES TO PREVENT AGGREGATION - A system and method for preventing protein aggregation is developed by covalent modification of proteins with organic molecules that can preserve the native protein folding. Proteins are covalently modified with sugar alcohols or cyclodextrins (organic Kosmotropes) or other small molecule drugs by water-driven bioorganic reactions in water. In the water-driven bioorganic reactions, the reagent is stable in water and can modify lysine residues or cysteine residue of a protein at physiological conditions with high yield and fast rate. Proteins and antibodies will be modified by non-natural sugar alcohols. As a result, the efficacy of protein drugs (reduction in aggregation and enzymatic degradation, and increase in blood stream life time) may be improved. | 10-28-2010 |
20100280228 | PURIFICATION OF IMMUNOCONJUGATES - The present invention provides methods of purifying immunoconjugates. | 11-04-2010 |
20110028698 | Modified Chimeric Polypeptides with Improved Pharmacokinetic Properties - Modified chimeric polypeptides with improved pharmacokinetics are disclosed. Specifically, modified chimeric Flt1 receptor polypeptides that have been modified in such a way as to improve their pharmacokinetic profile are disclosed. Also disclosed are methods of making and using the modified polypeptides including but not limited to using the modified polypeptides to decrease or inhibit plasma leakage and/or vascular permeability in a mammal. | 02-03-2011 |
20110077385 | Protein arrays - The invention provides proteins attached to solid supports, and methods of preparing such solid support-bound proteins are provided. The proteins are attached to solid supports by means of an unnatural amino acid incorporated into the protein, which unnatural amino acid includes a reactive group that can react with a second reactive group that is attached to a solid support. | 03-31-2011 |
20110092677 | MODIFIED TRANSFERIN-ANTIBODY FUSION PROTEINS - Modified fusion proteins of transferrin and therapeutic proteins or peptides, preferably antibody variable regions, with increased serum half-life or serum stability are disclosed. Preferred fusion proteins include those modified so that the transferrin moiety exhibits no or reduced glycosylation, binding to iron and/or binding to the transferrin receptor. | 04-21-2011 |
20110160440 | Cab Molecules - The present invention relates to CAB molecules, ADEPT constructs directed against CEA, and their use in diagnosis and therapy. | 06-30-2011 |
20110263832 | SITE-SPECIFIC MODIFICATION OF PROTEINS THROUGH CHEMICAL MODIFICATION ENABLING PROTEIN CONJUGATES, PROTEIN DIMER FORMATION, AND STAPLED PEPTIDES - The present invention generally provides methods for the site-specific modification of peptides, polypeptides, and proteins, e.g., granulocyte macrophage colony-stimulating factor, human superoxide dismutase, annexin, leptin, antibodies and the like, cytokines and chemokines, at their N-termini and at sites at which unnatural aminoacids have been introduced along the protein framework. The modifications described herein can be used for the synthesis and application of the adducts in radio-labeling, molecular imaging and protein therapeutic applications, and the treatment of disorders such as rheumatoid arthritis, lupus erythematosus, psoriasis, multiple sclerosis, type-1 diabetes, Crohn's disease, and systemic sclerosis, Alzheimer disease, cancer, liver disease (e.g., alcoholic liver disease), and cachexia. | 10-27-2011 |
20110269942 | ANTIBODIES MODIFIED WITH HYDROPHOBIC MOLECULE - The present invention relates to an immunoliposome preparation or a hydrophobic molecule-modified antibody having a therapeutic effect on cancer, autoimmune disease, or inflammatory disease. Specifically, the present invention relates to an immunoliposome or a hydrophobic molecule-modified antibody comprising, as a constituent, an antibody capable of inducing the apoptosis of cells expressing a death domain-containing receptor. | 11-03-2011 |
20110301337 | NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 12-08-2011 |
20110301338 | NOVEL INHIBITORS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ACTIVITY, THEIR USES AND PROCESSES FOR THEIR PRODUCTION - The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization. | 12-08-2011 |
20110319601 | Inorganic Particle Conjugates - The ionic conjugates include an inorganic particle electrostatically associated with a macromolecule which can interact specifically with predetermined chemical species or biological targets. | 12-29-2011 |
20130041140 | Preparation and/or Purification of Oligonucleotide Conjugates - Methods, systems and/or kits for the preparation, purification and isolation of oligonucleotide conjugates, comprising conjugation of modified antibodies or proteins with at least one modified oligonucleotide at greater than 80% efficiency to form oligonucleotide conjugates and isolating the oligonucleotide conjugates from the conjugation solution by binding the conjugates to an immobilized binder, wherein the binder may be a metal ion or an antibody. | 02-14-2013 |
20130041141 | FLUORESCENT POLYMER COMPOSITION - This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (≦5 mm) and a high molecular weight polymer (≧1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked FICOLL® molecule having a plurality of binding molecules and a plurality of fluorescent labels. | 02-14-2013 |
20130066054 | MULTIVALENT ANTIBODIES - A multivalent antibody fusion protein comprising: a heavy chain comprising, in sequence from the N-terminal, a variable domain nominally V | 03-14-2013 |
20130150562 | METHOD FOR IMMOBILIZATION, PHYSIOLOGICALLY ACTIVE SUBSTANCE-IMMOBILIZED CARRIER, CARRIER FOR IMMOBILIZATION, CARRIER, AND PROCESS FOR PRODUCING CARRIER - An immobilization method for immobilizing a physiologically active substance on a solid phase carrier, the method including: bringing the solid phase carrier into contact with an acid anhydride functional group-containing silane coupling agent represented by the following Formula (I); and carrying out a process of binding of the physiologically active substance to the acid anhydride functional group while maintaining the solid phase carrier after the contact at a temperature within the range of 0° C. to 60° C.; a physiologically active substance-immobilized carrier, and a carrier for immobilization are provided. Further, a carrier including a porous material treated with an acid anhydride functional group-containing silane coupling agent represented by the following Formula (I), a blocking agent that is immobilized to the porous material; and a method for producing it is provided. | 06-13-2013 |
20130150563 | LIPID-CONJUGATED ANTIBODIES - The present invention relates to novel lipid-conjugated antibodies for use in the treatment or the prevention of diseases, including but not limited to cancer, metabolic diseases including but not limited to hyperglycemia and diabetes, obesity, hypertension, hypercholesterolemia, allergy, asthma, Alzheimer's disease, and infectious diseases including but not limited to diseases caused by viruses, bacteria and fungi. | 06-13-2013 |
20130289251 | BINDING AGENT - A binding agent of the Formula A-a′:a-S-b:b′-B:X(n), wherein A as well as B is a monovalent binder, a′:a as well as b:b′ is a binding pair wherein a′ and a do not interfere with the binding of b to b′ and vice versa, S is a spacer of at least 1 nm in length, :X denotes a functional moiety bound either covalently or via a binding pair to at least one of a′, a, b, b′ or S, (n) is an integer and at least 1, - represents a covalent bond, and the linker a-S-b has a length of 6 to 100 nm. Also disclosed are methods of producing such binding agent and certain uses thereof. | 10-31-2013 |
20140018524 | PROTEINACEOUS-SUBSTANCE-BINDING LOW-MOLECULAR-WEIGHT COMPOUND - The low-molecular-weight compound represented by the general formula (1): ArX-(Linker)-ArYHB (1), wherein ArX is a structure containing an optionally substituted aromatic six-membered ring, ArYHB is a structure containing an optionally substituted aromatic six-membered ring having a proton donor, the atom group “Linker” has not less than 4 and not more than 30 atoms and binds ArX with ArYHB, is used for binding a proteinaceous substance. | 01-16-2014 |
20140081004 | GLYCOSYLATED SPECIFICITY EXCHANGERS - The present invention is directed to ligand/receptor and antigen/antibody specificity exchangers comprising a saccharide or glycoconjugate. Methods of making these specificity exchangers and methods of using said specificity exchangers to treat or prevent human disease are described herein. | 03-20-2014 |
20150018533 | REPEBODY AGAINST IMMUNOGLOBULIN G AND USES THEREOF - The present invention relates to a polypeptide (repebody) selectively bound to an immunoglobulin G, a polynucleotide which encodes the repebody, a vector containing the polynucleotide, a recombinant microorganism in which the polynucleotide is introduced, a method for producing the repebody using the recombinant microorganism, and a method for immobilizing or purifying an immunoglobulin G using the repebody. The repebody according to the present invention is useful as utilized for immobilization of an immunoglobulin G, purification of an immunoglobulin G, and production of an immunosensor, since the repebody selectively bound to an immunoglobulin G. | 01-15-2015 |
20150018534 | ANTIBODY-IMMOBILIZED CARRIER, METHOD OF PRODUCING ANTIBODY-IMMOBILIZED CARRIER, AND USE OF SAID ANTIBODY-IMMOBILIZED CARRIER - The present invention provides an antibody-immobilized carrier that can be used in antibody screening, a method of producing the antibody-immobilized carrier, and use of the antibody-immobilized carrier. Efficient antibody screening can be carried out particularly by an antibody-immobilized carrier including two or more antibody immobilized regions onto each of which a heavy-chain low-molecular-weight antibody and a light-chain low-molecular-weight antibody are separately immobilized, the two or more antibody immobilized regions each being included in an independent manner, the heavy-chain low-molecular-weight antibody including a heavy-chain variable region, the light-chain low-molecular-weight antibody including a light-chain variable region, the heavy-chain low-molecular-weight antibody and the light-chain low-molecular-weight antibody each being derived from an antibody recognizing a different antigen. | 01-15-2015 |
20150057438 | SURFACE-BOUND FLUORINATED ESTERS FOR AMINE CAPTURE - A method for immobilizing an amino-containing material to a substrate is described. The method involves providing a tethering compound with two reactive groups: a substrate reactive group and a fluoroalkoxycarbonyl group. The method further involves preparing a substrate-attached tethering group by reacting the substrate reactive group of the tethering compound with a complementary functional group on the surface of a substrate. The substrate-attached tethering group has a fluoroalkoxycarbonyl group that can be reacted with an amino-containing material to form an immobilization group that connects the amino-containing material to the substrate. | 02-26-2015 |
20150291699 | PICTET-SPENGLER LIGATION FOR PROTEIN CHEMICAL MODIFICATION - Aldehyde- and ketone-functionalized proteins are promising new substrates for the development of chemically modified biotherapeutics and protein-based materials. Their reactive carbonyl groups are typically conjugated with a-effect nucleophiles, such as substituted hydrazines and alkoxyamines, to generate hydrazones and oximes, respectively. However, the resulting C═N linkages are susceptible to hydrolysis under physiologically relevant conditions, which limits their utility in biological systems. Here we introduce a Pictet-Spengler ligation that is based on the classic Pictet-Spengler reaction of aldehydes and tryptamine nucleophiles. The ligation exploits the bioorthogonal reaction of aldehydes and alkoxyamines to form an intermediate oxyiminium ion; this intermediate undergoes intramolecular C—C bond formation with an indole nucleophile to form an oxacarboline product that is hydrolytically stable. The reaction was utilized for site-specific chemical modification of glyoxal- and formylglycine-functionalized proteins, including an aldehyde-tagged variant of the therapeutic monoclonal antibody Herceptin. In conjunction with techniques for site-specific introduction of aldehydes into proteins, the Pictet-Spengler ligation offers a new means to generate stable bioconjugates for medical and materials applications. | 10-15-2015 |
20150352217 | Pharmaceutical Compounds Targeted by MIF Affinity-Tethered Moieties - There is disclosed a compound, a pharmaceutical composition and a method of treatment using a pharmaceutical composition comprising a tethering moiety that is capable of binding to a macrophage migration inhibitory factor (MIF) polypeptide, optionally linked to a linker moiety and further covalently bound to a drug moiety or imaging agent. More specifically, there is disclosed a genus of affinity-tethering moieties covalently bound to a drug moiety or imaging agent either directly or optionally via a linker moiety to covalently link the tethering moiety to a drug moiety. Without being bound by theory, the disclosed pharmaceutical compounds are targeted to cancer cells or immune cells via an affinity-tethering moiety that hitch-hikes to or into its target cell while bound to endogenous MIF. | 12-10-2015 |
20160022833 | SOLID PHASE TGASE-MEDIATED CONJUGATION OF ANTIBODIES - Some embodiments described herein relate to solid-support based processess for the functionalization of immunoglobulins through the use of transglutaminase. Also provided are solid support compositions with bound antibody. The methods can be used, for example, in manufacturing processes or in drug screening. | 01-28-2016 |
20160074539 | TARGETING CONSTRUCTS - Gas-filled microvesicles associated with a polypeptide comprising a sequence of amino acids, said sequence exhibiting binding affinity for selectins, particularly p-selectin. The gas-filled microvesicles can be used in ultrasound imaging. | 03-17-2016 |
20160103126 | USE OF METAL COMPLEXES - A method of immobilising a target molecule on a substrate, which comprises exposing the target molecule to the substrate in the presence of a metal complex, wherein the target molecule is an unmodified target molecule, and wherein the metal complex is selected to provide a stable binding interaction between the target molecule and the substrate. | 04-14-2016 |
20160144042 | DESIGN AND DEVELOPMENT OF MASKED THERAPEUTIC ANTIBODIES TO LIMIT OFF-TARGET EFFECTS - In one embodiment, a masked monoclonal antibody (mAb) is provided, the mAb, encoded by a nucleic acid sequence or an amino acid sequence molecule comprising a signal sequence, a masking epitope sequence, a linker sequence that is cleavable by a protease specific to a target tissue; and an antibody or a functional fragment thereof. In another embodiment, a masked monoclonal antibody (mAb) is provided, which includes a therapeutic mAb and a mask, the mask comprising protein A and protein L attached by a protease cleavable linker. | 05-26-2016 |
20160176811 | Amino Acid Derivatives | 06-23-2016 |
20160194410 | BINDING AGENT | 07-07-2016 |